Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;18(9):e2100336.
doi: 10.1002/cbdv.202100336. Epub 2021 Aug 9.

Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings

Wanessa Santana  1 , Simone S C de Oliveira  2 , Mariana H Ramos  1 , André L S Santos  2 , Silvio S Dolabella  3 , Eliana B Souto  4   5 , Patrícia Severino  1   6 , Sona Jain  1
Affiliations
Review

Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings

Wanessa Santana et al. Chem Biodivers. 2021 Sep.

Abstract

Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo), drug repurposing and clinical research.

Keywords: clinical; drug repurposing; leishmaniasis; new targets; pre-clinical.

PubMed Disclaimer

References

    1. S. S. Oliveira, C. S. Ferreira, M. H. Branquinha, A. L. Santos, M. V. Chaud, S. Jain, J. C. Cardoso, A. B. Kovačević, E. B. Souto, P. Severino, ‘Overcoming multi-resistant leishmania treatment by nanoencapsulation of potent antimicrobials’, J. Chem. Technol. Biotechnol. 2021, 96, 2123-2140.
    1. H. Akuffo, C. Costa, J. van Griensven, S. Burza, J. Moreno, M. Herrero, ‘New insights into leishmaniasis in the immunosuppressed’, PLoS Neglected Trop. Dis. 2018, 12, e0006375.
    1. E. B. Souto, J. Dias-Ferreira, S. A. Craveiro, P. Severino, E. Sanchez-Lopez, M. L. Garcia, A. M. Silva, S. B. Souto, S. Mahant, ‘Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems’, Pathogenesis 2019, 8.
    1. N. E. Aronson, ‘Addressing a clinical challenge: Guidelines for the diagnosis and treatment of leishmaniasis’, BMC Med. 2017, 15, 1-3.
    1. E. Torres-Guerrero, M. R. Quintanilla-Cedillo, J. Ruiz-Esmenjaud, R. Arenas, ‘Leishmaniasis: a review’, F1000Research 2017, 6.

MeSH terms

Substances

LinkOut - more resources